非小细胞肺癌β-微管蛋白Ⅲ表达及其与含紫杉醇方案耐药的关系  

Relationship between β-tubulin Ⅲ expression and paclitaxel-containing regimen with drug resistance in non small-cell lung cancer

作　　者：刘萍[1] 王豪勋[1] 王海莉[1] 

机构地区：[1]郑州大学第二附属医院肿瘤科,河南郑州450014

出　　处：《实用临床医药杂志》2013年第3期12-15,共4页Journal of Clinical Medicine in Practice

基　　金：中国高校医学期刊临床专项资金(11220261)

摘　　要：目的探讨晚期非小细胞肺癌(NSCLC)组织中β-微管蛋白Ⅲ(β-tubulinⅢ)的表达及其与含紫杉醇方案耐药的关系。方法经病理学确诊为ⅢBⅣ期的120例NSCLC患者随机分为2组,试验组60例给予紫杉醇/顺铂(TP)方案,对照组60例给予长春瑞滨/顺铂(NP)方案,2个周期后评价疗效。应用免疫组化法检测120例NSCLC组织中β-tubulinⅢ的表达并分析其与含紫杉醇方案耐药的关系。结果 NSCLC组织中β-tubulinⅢ表达水平与患者年龄、性别、分期及组织学类型无关。β-tubulinⅢ高表达与TP方案化疗耐药有关:TP方案化疗耐药者β-tubulinⅢ的高表达率为77.3%,明显高于敏感者的42.1%。β-tubulinⅢ高表达与NP方案化疗耐药无关。结论β-tubulinⅢ在NSCLC组织中的表达水平与含紫杉醇方案耐药有关。Objective To determine the relationship between the expression of β-tubulin IU and paclitaxel-containing regimen with drug resistance in non small-cell lung cancer （NSCLC）. Methods A total of 120 NSCLC patients were randomly divided into two groups. The treatment group （60 cases） was treated with TP regimen, the control group （60 cases） with NP regimen. All patients had received 2 cycles chemotherapy. The β-tubulin m expression of 108 NSCLC patients were examined via immunohistochemical method and the relationship between the β-tubulin Ⅲ expression and paelita- xel-containing regimen with drug resistance were analyzed. Results β-tubulin Ⅲ expression level did not show any association with patient age, sex, clinical stage and histology type. The expression of β- tubulin Ⅲ was associated with paclitaxel resistance in NSCLC. The high expression rate of β-tubulin Ⅲ in chemo-resistant patients was 77.3 %, and that of chemo-sensitive patients was 42.1%. The expression of β-tubulin m was not associated with vinorelbine resistance in NSCLC. Condusion The expression of β-tubulin m in NSCLC is related to paclitaxel-containing regimen resistance, which shows predictive value to chemoresistance in NSCLC.

关 键 词：非小细胞肺癌 β-微管蛋白Ⅲ 紫杉醇 耐药 

分 类 号：R734.2[医药卫生—肿瘤]